During the fourth quarter of 2025, Intuitive Surgical’s procedure growth in Japan remained below management expectations and face-off reimbursement guidelines that begin June 2026 have yet to catalyze a rebound. Compounding this, the company is losing ground in China as provincial tenders now favor local robotic suppliers offering lower pricing. CEO David Rosa noted that the proliferation of Chinese competitors—many with comparable technology—has eroded Intuitive’s historical pricing power and led to more aggressive discounting in major tenders. Intuitive’s next-generation Ion endoluminal system saw a meaningful slowdown in unit placements during Q4, with only 42 installations compared to 69 in the year-ago period. CFO Jamie Samath attributed the drop to existing U.S. customers prioritizing higher utilization rates—up 11% year-over-year—over new system purchases. While greater utilization supports recurring revenue, the decline in new system orders underscores emerging bottlenecks in the product’s growth trajectory. For 2026, Intuitive now projects da Vinci procedure volume growth of just 13%–15%, down from an 18% increase delivered in 2025. Vice President of Investor Relations Dan Connally pointed to capital constraints in select European markets and pending changes to U.S. Affordable Care Act premium subsidies and Medicaid funding as key headwinds. This deceleration in core procedure growth represents a material shift in the company’s growth profile and could pressure both system and accessory revenues. A comprehensive 20-year retrospective study published in the Annals of Surgery in November 2025 found that patients undergoing robotic-assisted procedures were 50% less likely to require subsequent open surgery than those treated laparoscopically. Investors view this data as validation of robotic surgery’s clinical benefits and a potential catalyst for broader adoption across an estimated 20 million soft-tissue cases annually—an addressable market that could drive long-term instrument, accessory, and service revenue growth.